Follow A Race Against Blindness research funding, inherited retinal disease developments, community stories, grant announcements, and updates from families racing toward sight-saving treatments.
Good Morning America, Phoenix and Seattle TV, Ophthalmology Times, OVR Magazine and more have covered A Race Against Blindness. The coverage, the research partners and the sponsors, with links.
Every dollar below has been paid out to research, made possible by the generosity of our sponsors and donors. Real people making an impact on saving children's eyesight.
$7.1M
total research funding, fully paid out · as of November 2026
2024
$3M awarded
October
$1M
December
$2M — announced Feb 2025
To fund the preclinical development and regulatory preparation of AXV-101, a gene therapy for Bardet-Biedl Syndrome type 1 (BBS1), advancing the program toward its first human clinical trial.
2025
$2.1M awarded
September
$1M
December
$1.1M — announced Jan 2026
To support clinical development of the first-in-human trial, including trial preparation and regulatory progress following clinical trial clearance, and to close the remaining funding gap required to launch the AXV-101 clinical trial, enabling the study to begin in early 2026.
2026
$2M awarded
June
$1M
November
$1M
Through two grants to the Foundation Fighting Blindness, to fund gene-agnostic research: in June, the Gund Vision Fund (formerly the RD Fund) and early-stage gene therapy delivery research with Dr. Thomas Mendel; in November, the Gund Vision Fund and regenerative research with Dr. Jin Woo Kim at KAIST. The Gund Foundation Challenge matched the $1,475,000 directed to the Fund dollar for dollar.
Supporters share heartfelt messages of hope, personal stories, and encouragement as a clinical trial milestone brings new possibility to children facing blindness.